NextCure stockholders elect directors, ratify auditor, approve reverse stock split at 2025 annual meeting

NextCure, Inc.

Elected Class III directors David Kabakoff, Michael Richman, and Stephen W. Webster for three-year terms expiring 2028.
Ratified Ernst & Young LLP as independent auditor for fiscal year 2025 with 18.8M for, 1.4M against.
Approved say-on-pay (11.3M for, 0.4M against) and frequency vote of every year (11.7M for).
Approved amendment to certificate of incorporation to authorize reverse stock split when determined by the Board (18.2M for, 2.0M against).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.